查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年全球新生兒篩檢市場
市場調查報告書
商品編碼
1380456

2023-2030 年全球新生兒篩檢市場

Global Newborn Screening Market 2023-2030
出版日期: | 出版商: Orion Market Research | 英文 175 Pages | 商品交期: 2-3個工作天內

價格

全球新生兒篩檢市場預計在預測期內（2023-2030年）CAGR為7.8%。市場的成長歸功於早期介入。在醫療保健領域，早期介入對於改善患者的治療效果變得越來越重要。現代科技有助於實現新生兒篩檢的基本目標。因此，市場參與者正在推出新產品來滿足對新篩檢設備的需求。例如，2023 年 9 月，MyLab 推出了一款革命性的照護端新生兒篩檢設備，名為 My NeoShield，用於新生兒篩檢。該技術預計將改變新生兒保健的方法，促進更快、更容易、更經濟的篩檢，最終可以挽救生命並防止疾病發展為終身疾病。該設備支援全球新生兒篩檢所使用的所有七項測試。

細分市場前景

全球新生兒篩檢市場按技術、測試類型和最終用戶進行細分。根據技術，市場細分為串聯質譜、LC-MS/MS、脈搏血氧測定、DNA 微陣列和 NGS、酵素檢測等。根據測試類型，市場細分為血斑篩檢（乾血斑測試）、聽力篩檢（耳聲發射和聽性腦幹反應）、脈搏血氧飽和度篩檢、CCHD 等。此外，根據最終用戶，市場被細分為醫院和分娩中心、NIUC、診斷中心、研究人員和科學家等。醫院和分娩中心子類別預計將佔據最終用戶領域的很大一部分市場佔有率。可支配收入的增加、患者住院需求的增加、新生兒疾病盛行率的增加、高科技醫院和醫療基礎設施的發展是推動市場成長的其他因素。

聽力篩檢細分市場預計將在全球新生兒篩檢市場中佔據相當大的佔有率

在測試類型中，聽力篩檢細分市場預計將在全球新生兒篩檢市場中佔據相當大的佔有率。節段性成長歸因於新生兒聽力損失的普遍存在。上述比率強調了新生兒聽力篩檢計劃的重要性。根據美國國立衛生研究院(NIH.gov) 的數據，2022 年10 月，每1000 名活產嬰兒中，有1 至1.5 次發生新生兒患有嚴重或深度PBHL（損失>60 dB [dB]）的情況。每 1000 名嬰兒中，有 1 至 2 名嬰兒出現雙側輕度至中度聽力損失或任何嚴重程度的單側聽力損失。嚴重和深度 PBHL 都會嚴重阻礙語言和識字能力的發展、成人功能和生活品質.

區域展望

全球新生兒篩檢市場根據地理位置進一步細分，包括北美（美國和加拿大）、歐洲（英國、義大利、西班牙、德國、法國和歐洲其他地區）、亞太地區（印度、中國、日本） 、韓國和亞洲其他地區）以及世界其他地區（中東和非洲以及拉丁美洲）。其中，由於存在強大的市場競爭對手、有利的報銷政策以及新生兒篩檢計劃的可用性，預計北美將在全球市場中佔據顯著佔有率。

歐洲地區全球新生兒篩檢市場預計將以顯著的複合CAGR成長

在所有地區中，歐洲地區預計在預測期內將以相當大的CAGR成長。區域成長歸因於該地區診斷效率的不斷提高。新生兒全基因組定序是一種有效的診斷工具，可以發現多種遺傳異常，甚至罕見疾病。透過早期檢測和干涉，這種程度的診斷準確性可以大大提高新生兒篩檢的效率。政府和該地區的市場參與者擴大引入此類新的診斷工具和舉措，以提供更好的新生兒醫療保健服務。例如，2022 年 12 月，英國政府啟動了新生兒基因組計劃，這是一項新研究，旨在檢驗全基因組定序在識別新生兒罕見疾病方面的效率。除了血斑檢測之外，新生兒的全基因組定序還發現了數千種罕見疾病，並顯著改善了患有上述疾病的兒童的生活品質。歐洲市場參與者和政府正在透過部署不同的行銷策略為新生兒篩檢市場的快速發展創造有利條件。

此外，2021年9月，英國公共衛生部（PHE）、英國國家篩檢委員會（UK NSC）、英國國民醫療服務體系（NHS England）和國民保健服務改善局（NHSEI）在英國啟動了針對新生兒嚴重聯合免疫缺陷（SCID）血斑篩檢的評估。

目錄

第 1 章：報告摘要

  • 目前行業分析及成長潛力展望
  • 研究方法和工具
  • 市場區隔
    • 按細分
    • 按地區

第 2 章：市場概述與見解

  • 報告範圍
  • 分析師見解和當前市場趨勢
    • 主要發現
    • 建議
    • 結論

第 3 章：競爭格局

  • 主要公司分析
  • At Demant A/S,
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • Bio-Rad Laboratories, Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • GE HealthCare Technologies Inc.
    • 概述
    • 財務分析
    • SWOT分析
    • 最近的發展
  • 關鍵策略分析

第 4 章：市場細分

  • 按技術分類的全球新生兒篩檢市場
    • 串聯質譜法
    • 液相層析質譜聯用 (LC-MS/MS)
    • 脈搏血氧儀
    • DNA 微陣列和次世代定序 (NGS)
    • 基於酵素的測定
    • 其他（高效液相層析法 (HPLC)、免疫比濁法和免疫化學）
  • 按測試類型分類的全球新生兒篩檢市場
    • 血斑篩檢（乾血斑測試）
    • 聽力篩檢（耳聲發射和聽覺腦幹反應）
    • 脈搏血氧儀篩檢
    • 嚴重先天性心臟缺陷 (CCHD)
    • 其他（甲狀腺功能測試、汗液氯化物測試和凝血研究（PT/INR 和 APTT）
  • 按最終用戶分類的全球新生兒篩檢市場
    • 醫院和分娩中心
    • 新生兒加護病房 (NICU)
    • 診斷中心
    • 研究人員和科學家
    • 其他（醫療保健管理員、醫生和兒科醫生以及實驗室）

第 5 章：區域分析

  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 歐洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 世界其他地區

第 6 章：公司簡介

  • Hill-Rom Holdings, Inc.,
  • India Medtronic Pvt. Ltd.
  • Integrated DNA Technologies
  • LifeCell International Pvt. Ltd.
  • Masimo Corp.
  • PerkinElmer AES
  • SCIEX
  • Thermo Fisher Scientific Inc.,
  • Trivitron Healthcare
  • WATERS CORP.
  • ZenTech SA
Product Code: OMR2027763

Title: Global Newborn Screening Market Size, Share & Trends Analysis Report by Technology (Tandem Mass Spectrometry, Liquid Chromatography-Mass Spectrometry (LC-MS/MS), Pulse Oximetry, DNA Microarrays and Next-Generation Sequencing (NGS), Enzyme Based Assays, and Others), by Test Type (Blood Spot Screening, Hearing Screening, Pulse Oximetry Screening, Critical Congenital Heart Defect (CCHD), and Others), and by End-User (Hospitals and Birthing Centers, Neonatal Intensive Care Units (NICUs), Diagnostic Centers, Researchers and Scientists, and Others)Forecast Period (2023-2030).

The global newborn screening market is anticipated to grow at a CAGR of 7.8% during the Forecast Period (2023-2030). The market's growth is attributed to early intervention. Early intervention has become more and more essential in healthcare to enhance patient outcomes. Modern technologies help to achieve the essential goal of newborn screening. Accordingly, market players are coming up with new products to cater to the demand for new screening devices. For instance, in September 2023, MyLab introduced a revolutionary point-of-care newborn screening device named My NeoShield for newborn screening. The technology is expected to change the methods by that neonatal healthcare is provided by facilitating quicker, easier, and more economical screening, that can ultimately save lives and prevent diseases from developing into lifelong conditions. All seven tests used for newborn screening across the globe are supported by the device.

Segmental Outlook

The global newborn screening market is segmented on the technology, test type, and end-user. Based on the technology, the market is sub-segmented into tandem mass spectrometry, LC-MS/MS, pulse oximetry, DNA microarrays and NGS, enzyme based assays, and others. Based on the test type, the market is sub-segmented into blood spot screening (dried blood spot test), hearing screening (otoacoustic emissions and auditory brainstem response), pulse oximetry screening, CCHD, and others. Furthermore, based on the end-user, the market is sub-segmented into hospitals and birthing centers, NIUCs, diagnostic centers, researchers and scientists, and others. The hospitals and birthing centers subcategory is expected to capture a significant portion of the market share within the end-user segment. Rising disposable income along with a rise in patient hospitalization needs, increased prevalence of newborn diseases high-tech hospitals and healthcare infrastructure developments are additional factors propelling the market's growth.

The Hearing Screening Sub-Segment is Anticipated to Hold a Considerable Share of the Global Newborn Screening Market

Among the test types, the hearing screening sub-segment is expected to hold a considerable share of the global newborn screening market. The segmental growth is attributed to the prevalence of newborn hearing loss. The significance of newborn hearing screening programs is emphasized by the aforementioned rate. According to the National Institute of Health (NIH.gov), in October 2022, it occurs 1 to 1.5 times per 1000 live births when a neonate has severe or profound PBHL (loss of >60 dB [dB]). Bilateral mild to moderate hearing loss or unilateral hearing loss of any severity affects 1 to 2 more infants every 1000. The development of language and literacy, adult functioning, and quality of life are all significantly hindered by both severe and profound PBHL.

Regional Outlook

The global newborn screening market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the presence of strong market competitors, advantageous reimbursement policies, and the availability of newborn screening programs.

The European Region is Expected to Grow at a Significant CAGR in the Global Newborn Screening Market

Among all regions, the European region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the rising improvement in diagnostic efficiency across the region. Newborns' whole genome sequencing is an effective diagnostic tool that can spot a variety of genetic abnormalities, even rare diseases. By enabling early detection and intervention, this degree of diagnostic accuracy can considerably improve the efficiency of newborn screening. The government along with the market players operating in the region are increasingly introducing such new diagnostic tools and initiatives to provide improved newborn healthcare services. For instance, in December 2022, the UK Government launched the Newborn Genomes Programme, a new study that examines the efficiency of whole genome sequencing in identifying uncommon disorders in newborn babies. In addition to the blood spot test, whole genome sequencing of newborns identified thousands of uncommon diseases and significantly improved the quality of life for children born with the aforementioned conditions. European market players and governments are creating favorable conditions for the rapid development of the newborn screening market by deploying different marketing strategies.

Furthermore, in September 2021, Public Health England (PHE), the UK National Screening Committee (UK NSC), NHS England, and NHS Improvement (NHSEI) launched an evaluation of newborn blood spot screening for severe combined immunodeficiency (SCID) in England.

Market Players Outlook

The major companies serving the newborn screening market include: Hill-Rom Holdings, Inc., India Medtronic Pvt. Ltd., Integrated DNA Technologies, LifeCell International Pvt. Ltd., Masimo Corp. and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in June 2023, Eight taluk hospitals announced to launch a newborn screening. For which, the Mysuru-based All India Institute of Speech and Hearing (AIISH) collaborated with the Department of Health and Family Welfare for briefing the medical teams working under Rashtriya Bal Swasthya Karyakram (RBSK) and District Early Intervention Centre (DEIC) on screening communication disorders in children. The initiative is introduced post recognizing the need for expanding the Newborn Screening Programme (NBS).

The Report Covers:

  • Market value data analysis of 2022 and forecast to 2030.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global newborn screening market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies.
  • Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. At Demant A/S,
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Bio-Rad Laboratories, Inc.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. GE HealthCare Technologies Inc.
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Newborn Screening Market by Technology
    • 4.1.1. Tandem Mass Spectrometry
    • 4.1.2. Liquid Chromatography-Mass Spectrometry (LC-MS/MS)
    • 4.1.3. Pulse Oximetry
    • 4.1.4. DNA Microarrays and Next-Generation Sequencing (NGS)
    • 4.1.5. Enzyme Based Assays
    • 4.1.6. Others (High-Performance Liquid Chromatography (HPLC), and Immunoturbidimetry and Immunochemistry)
  • 4.2. Global Newborn Screening Market by Test Type
    • 4.2.1. Blood Spot Screening (Dried Blood Spot Test)
    • 4.2.2. Hearing Screening (Otoacoustic Emissions and Auditory Brainstem Response)
    • 4.2.3. Pulse Oximetry Screening
    • 4.2.4. Critical Congenital Heart Defect (CCHD)
    • 4.2.5. Others (Thyroid Function Testing, Sweat Chloride Test, and Coagulation Studies (PT/INR and APTT)
  • 4.3. Global Newborn Screening Market by End-User
    • 4.3.1. Hospitals and Birthing Centers
    • 4.3.2. Neonatal Intensive Care Units (NICUs)
    • 4.3.3. Diagnostic Centers
    • 4.3.4. Researchers and Scientists
    • 4.3.5. Others (Healthcare Administrators, Physicians and Pediatricians, and Laboratories)

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World

6. Company Profiles

  • 6.1. Hill-Rom Holdings, Inc.,
  • 6.2. India Medtronic Pvt. Ltd.
  • 6.3. Integrated DNA Technologies
  • 6.4. LifeCell International Pvt. Ltd.
  • 6.5. Masimo Corp.
  • 6.6. PerkinElmer AES
  • 6.7. SCIEX
  • 6.8. Thermo Fisher Scientific Inc.,
  • 6.9. Trivitron Healthcare
  • 6.10. WATERS CORP.
  • 6.11. ZenTech SA

LIST OF TABLES

  • 1. GLOBAL NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 2. GLOBAL TANDEM MASS SPECTROMETRY NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 3. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 4. GLOBAL PULSE OXIMETRY NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 5. GLOBAL DNA MICROARRAYS AND NEXT-GENERATION SEQUENCING NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 6. GLOBAL ENZYME BASED ASSAYS NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 7. GLOBAL OTHERS NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 8. GLOBAL NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
  • 9. GLOBAL NEWBORN BLOOD SPOT SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 10. GLOBAL NEWBORN HEARING SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 11. GLOBAL NEWBORN CRITICAL CONGENITAL HEART DEFECT SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 12. GLOBAL NEWBORN OTHERS SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 13. GLOBAL NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END-USER, 2022-2030 ($ MILLION)
  • 14. GLOBAL NEWBORN SCREENING FOR HOSPITALS AND BIRTHING CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 15. GLOBAL NEWBORN SCREENING FOR NEONATAL INTENSIVE CARE UNITS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 16. GLOBAL NEWBORN SCREENING FOR DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 17. GLOBAL NEWBORN SCREENING FOR RESEARCHERS AND SCIENTISTS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 18. GLOBAL NEWBORN SCREENING FOR OTHERS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 19. GLOBAL NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
  • 20. NORTH AMERICAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 21. NORTH AMERICAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 22. NORTH AMERICAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
  • 23. NORTH AMERICAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 24. EUROPEAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 25. EUROPEAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 26. EUROPEAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
  • 27. EUROPEAN NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 28. ASIA- PACIFIC NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 29. ASIA- PACIFIC NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 30. ASIA- PACIFIC NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
  • 31. ASIA- PACIFIC NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)
  • 32. REST OF THE WORLD NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TECHNOLOGY, 2022-2030 ($ MILLION)
  • 34. REST OF THE WORLD NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY TEST TYPE, 2022-2030 ($ MILLION)
  • 35. REST OF THE WORLD NEWBORN SCREENING MARKET RESEARCH AND ANALYSIS BY END USER, 2022-2030 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL NEWBORN SCREENING MARKET SHARE BY TECHNOLOGY, 2022 VS 2030 (%)
  • 2. GLOBAL TANDEM MASS SPECTROMETRY NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 3. GLOBAL LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 4. GLOBAL PULSE OXIMETRY NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 5. GLOBAL DNA MICROARRAYS AND NEXT-GENERATION SEQUENCING NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 6. GLOBAL ENZYME BASED ASSAYS NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 7. GLOBAL OTHERS NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 8. GLOBAL NEWBORN SCREENING MARKET SHARE BY TEST TYPE, 2022 VS 2030 (%)
  • 9. GLOBAL NEWBORN BLOOD SPOT SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 10. GLOBAL NEWBORN HEARING SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 11. GLOBAL NEWBORN CRITICAL CONGENITAL HEART DEFECT SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 12. GLOBAL NEWBORN OTHERS SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 13. GLOBAL NEWBORN SCREENING MARKET SHARE BY END USER, 2022 VS 2030 (%)
  • 14. GLOBAL NEWBORN SCREENING FOR HOSPITALS AND BIRTHING CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 15. GLOBAL NEWBORN SCREENING FOR NEONATAL INTENSIVE CARE UNITS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 16. GLOBAL NEWBORN SCREENING FOR DIAGNOSTIC CENTERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 17. GLOBAL NEWBORN SCREENING FOR RESEARCHERS AND SCIENTISTS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 18. GLOBAL NEWBORN SCREENING OTHERS MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 19. GLOBAL NEWBORN SCREENING MARKET SHARE BY REGION, 2022 VS 2030 (%)
  • 20. US NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 21. CANADA NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 22. UK NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 23. FRANCE NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 24. GERMANY NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 25. ITALY NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 26. SPAIN NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 27. REST OF EUROPE NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 28. INDIA NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 29. CHINA NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 30. JAPAN NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 31. SOUTH KOREA NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 32. REST OF ASIA-PACIFIC NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)
  • 33. REST OF THE WORLD NEWBORN SCREENING MARKET SIZE, 2022-2030 ($ MILLION)